Sarepta Therapeutics

Scope of the Report:

As per the , Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It is a rare muscle disease, which majorly affects males. There are novel drugs and therapies, disease-modifying, and mutation-specific therapies that are some of the emerging major breakthroughs in the DMD treatment market.

The Report Covers:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999594

Key Market Trends:

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Segment is Expected to Grow Fastest During the Forecast Period

Corticosteroids are the only known pharmacological treatment for DMD and help to suppress muscle inflammation. This treatment is being limited by its inadequate therapeutic efficacy, and considerable side effects, and hence, non-steroidal anti-inflammatory drugs (NSAIDs) can be used to reduce the inflammation of muscles. The nonsteroidal anti-inflammatory drugs are expected to witness a CAGR of 49.2% over the forecast period.

However, other therapies and treatments include stem cell therapy, repurposing drugs, anti-fibrotics, myostatin inhibition, gene editing (CRISPR/Cas9), etc. Currently, prednisone/prednisolone and deflazacort have been used for the treatment of Duchenne muscular dystrophy, which is expected to drive the growth of the market, over the forecast period.

North American Region holds the Largest Market Share of the Market Currently and is Believed to Follow the Same Trend Over the Forecast Period

North America dominates the global Duchenne muscular dystrophy market, due to new product innovations, high healthcare expenditure, and government awareness programs. The United States has dominated the regional market and is projected to maintain its lead, owing to the rising disease incidence and anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with the increasing clinical trials around the world, especially in the United States and Europe.

Key Questions Answered in This Report:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/13999594

Detailed TOC of Duchenne Muscular Dystrophy Treatment Market 2019-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising Disease Burden of Duchenne Muscular Dystrophy (DMD) 4.2.2 Increasing Investments in Biopharmaceutical R&D to Release Novel Disease Therapies 4.2.3 Increasing Awareness Campaigns for DMD 4.3 Market Restraints 4.3.1 Lack of Standardization to Measure Clinical Efficacy Across All Stages of DMD 4.3.2 Stringent Regulatory Framework with High Product Cost Burden 4.4 Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Therapeutic Approach and Treatment Type 5.1.1 Molecular-based Therapies 5.1.1.1 Mutation Suppression 5.1.1.2 Exon Skipping 5.1.2 Steroid Therapy 5.1.2.1 Corticosteroids 5.1.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 5.1.4 Other Therapeutic Approaches and Treatment Types 5.2 By End User 5.2.1 Hospitals/Clinics 5.2.2 Ambulatory Centers 5.2.3 Other End Users 5.3 Geography 5.3.1 North America 5.3.1.1 United States 5.3.1.2 Canada 5.3.1.3 Mexico 5.3.2 Europe 5.3.2.1 Germany 5.3.2.2 United Kingdom 5.3.2.3 France 5.3.2.4 Italy 5.3.2.5 Spain 5.3.2.6 Rest of Europe 5.3.3 Asia-Pacific 5.3.3.1 China 5.3.3.2 Japan 5.3.3.3 India 5.3.3.4 Australia 5.3.3.5 South Korea 5.3.3.6 Rest of Asia-Pacific 5.3.4 Middle East & Africa 5.3.4.1 GCC 5.3.4.2 South Africa 5.3.4.3 Rest of Middle East & Africa 5.3.5 South America 5.3.5.1 Brazil 5.3.5.2 Argentina 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 BioMarin 6.1.2 Bristol-Myers Squibb Company 6.1.3 Fibrogen Inc. 6.1.4 Eli Lilly and Company 6.1.5 Nobelpharma Co. Ltd 6.1.6 NS Pharma Inc. 6.1.7 Pfizer Inc. 6.1.8 PTC Therapeutics 6.1.9 Santhera Pharmaceuticals 6.1.10 Sarepta Therapeutics

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Quantum Sensors Market 2020 Trends, Manufacturing Size, Growth Analysis by Share, Top Regions, Driving Factors of Manufacturers, Types and Applications Forecast to 2023

Cell Culture Reagent Market Size and Growth Rate 2020 | Global Impact of COVID-19 on Industry Share, Explosive Factors of Key Players, Progress Status, and Recent Trends Forecast to 2026

Polymer Stabilizing Agent Market Size and Growth Rate 2020 | Global Impact of COVID-19 on Industry Share, Explosive Factors of Key Players, Progress Status, and Recent Trends Forecast to 2026

Split Case Pumps Market Size by Top Key Players 2020 Global Growth Rate by Share, Industry Segment, Future Prospect, Key Finding and Market Dynamics Forecast to 2026

Liquid Chromatography-Mass Spectroscopy Market Growth Analysis by Top Key Players 2020 Consumption Capacity by Volume and Production Value, Trends Analysis, and Company Profiles till 2025

Read more here:
Duchenne Muscular Dystrophy Treatment Market Research Report 2020-2024 | Analysis by Key Regions, Manufacturing Technology and Development Forecast ...